Safety, pharmacokinetics, preliminary efficacy, pharmacodynamics, and immunogenicity of QX002N, an anti-IL-17A monoclonal antibody, after short-term treatment of active ankylosing spondylitis

Abstract Background To investigate the safety, pharmacokinetics, preliminary efficacy, pharmacodynamics, and immunogenicity of QX002N, an interleukin-17 A monoclonal antibody, in Chinese patients with active ankylosing spondylitis (AS). Methods In this phase 1b, double-blind, placebo-controlled, mul...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Min Wu, Qianqian Li, Min Fang, Hong Zhang, Yanhua Ding
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2025-05-01
Serie:	BMC Pharmacology and Toxicology
Soggetti:	QX002N Anti-IL-17A monoclonal antibody Safety Efficacy Pharmacokinetics Immunogenicity
Accesso online:	https://doi.org/10.1186/s40360-025-00885-4
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!